A randomised, double‐blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine†

By  

Human Psychopharmacology: Clinical And Experimental (Electronic), Vol. 30, Iss. 4, 2015-07 ,pp. : 327-327

John Wiley & Sons Inc

Access to resources Recommend Favorite

Aripiprazole Addition to Serotonin Reuptake Inhibitor in Treatment-Resistant Obsessive-Compulsive Disorder

By Shoja Shafti Saeed  

Current Psychopharmacology, Vol. 3, Iss. 3, 2014-12 ,pp. : 219-225

Bentham Science Publishers

Access to resources Recommend Favorite

Aripiprazole Addition to Serotonin Reuptake Inhibitor in Treatment-Resistant Obsessive-Compulsive Disorder

By  

Current Psychopharmacology, Vol. 3, Iss. 3, 2014-12 ,pp. : 219-225

Bentham Science Publishers

Access to resources Recommend Favorite

Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder

By Dell’Osso Bernardo   Allen Andrea   Hollander Eric  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 15, 2005-12 ,pp. : 2727-2740

Informa Healthcare

Access to resources Recommend Favorite

Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin–norepinephrine reuptake inhibitor

By Nichols Alice I   Tourian Karen A   Tse Susanna Y   Paul Jeffrey  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 6, Iss. 12, 2010-12 ,pp. : 1565-1574

Informa Healthcare

Access to resources Recommend Favorite